CY1114479T1 - Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος - Google Patents
Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματοςInfo
- Publication number
- CY1114479T1 CY1114479T1 CY20131100809T CY131100809T CY1114479T1 CY 1114479 T1 CY1114479 T1 CY 1114479T1 CY 20131100809 T CY20131100809 T CY 20131100809T CY 131100809 T CY131100809 T CY 131100809T CY 1114479 T1 CY1114479 T1 CY 1114479T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmacological
- introduction
- combination
- surgery
- tgf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Σύνθεση για έλεγχο ή αποτροπή εξέλιξης γλαυκώματος περιλαμβάνει υλικό που μειώνει ή αναστέλλει την παραγωγή ισόμορφης ΤGF-β ή χημειοκίνης ή κυτοκίνης που διεγείρει την έκφραση ισόμορφης ΤGF-β. Το υλικό μπορεί να περιλαμβάνει διαχωρισμένο αγωνιστή υποδοχέα γλυκοκορτικοειδούς (“DIGRA”: dissociated glucocorticoid receptor agonist), προφάρμακο αυτού, φαρμακευτικά αποδεκτό άλας αυτού, ή φαρμακευτικά αποδεκτό εστέρα αυτού. Η σύνθεση μπορεί επιπλέον να περιλαμβάνει ανταγωνιστή του ΤGF-β. Χορηγείται σε ασθενή που έχει υποβληθεί σε διηθητική χειρουργική επέμβαση γλαυκώματος για να εξασφαλίσει λειτουργική διηθητική φυσαλίδα μετά από τέτοια χειρουργική επέμβαση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97562007P | 2007-09-27 | 2007-09-27 | |
EP08799307.7A EP2203160B1 (en) | 2007-09-27 | 2008-09-08 | Pharmacological adjunctive treatment associated with glaucoma filtration surgery |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114479T1 true CY1114479T1 (el) | 2016-10-05 |
Family
ID=40043043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100809T CY1114479T1 (el) | 2007-09-27 | 2013-09-18 | Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090087443A1 (el) |
EP (1) | EP2203160B1 (el) |
JP (1) | JP5249336B2 (el) |
KR (1) | KR20100065166A (el) |
CN (1) | CN101878026B (el) |
AU (1) | AU2008305407B2 (el) |
BR (1) | BRPI0817472A2 (el) |
CA (1) | CA2699599C (el) |
CY (1) | CY1114479T1 (el) |
DK (1) | DK2203160T3 (el) |
ES (1) | ES2424008T3 (el) |
HK (1) | HK1145014A1 (el) |
HR (1) | HRP20130817T1 (el) |
MX (1) | MX2010003198A (el) |
PL (1) | PL2203160T3 (el) |
PT (1) | PT2203160E (el) |
SI (1) | SI2203160T1 (el) |
TW (1) | TWI366462B (el) |
WO (1) | WO2009042377A1 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045463A2 (en) * | 2008-10-15 | 2010-04-22 | Government Of The United States As Represented By The Secretary Of The Army | Clinical decision model |
US20110077270A1 (en) * | 2009-04-21 | 2011-03-31 | Pfeffer Bruce A | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure |
US10189773B2 (en) | 2010-05-07 | 2019-01-29 | Medicus Biosciences, Llc | In-vivo gelling pharmaceutical pre-formulation |
US11083821B2 (en) | 2011-08-10 | 2021-08-10 | C.P. Medical Corporation | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
US10111985B2 (en) * | 2011-08-10 | 2018-10-30 | Medicus Biosciences, Llc | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
CA2873105C (en) | 2012-05-11 | 2018-01-16 | Medicus Biosciences, Llc | Biocompatible hydrogel treatments for retinal detachment |
EA201891724A1 (ru) * | 2016-02-17 | 2019-01-31 | Новартис Аг | Антитела к tgf-бета2 |
US12027276B1 (en) | 2017-10-27 | 2024-07-02 | DecisionQ Corporation | Methods, systems and devices for assessing wound healing |
EP3914249B1 (en) | 2019-01-22 | 2024-05-01 | Akribes Biomedical GmbH | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
AU760562B2 (en) * | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
US6242196B1 (en) * | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
AU4713499A (en) * | 1998-06-27 | 2000-01-17 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
CA2472746A1 (en) * | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
ES2298508T3 (es) * | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
EP1490317A1 (en) * | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US6897224B2 (en) * | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003297363A1 (en) * | 2002-12-23 | 2004-07-22 | Alcon, Inc. | Use of cathepsin k inhibitors for the treatment of glaucoma |
CA2512257A1 (en) * | 2003-01-03 | 2004-07-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands |
US20040224992A1 (en) * | 2003-02-27 | 2004-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2004097410A1 (en) * | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Screening methods for cataractogenic risk |
UY28526A1 (es) * | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
US7795272B2 (en) * | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
JP2007530541A (ja) * | 2004-03-22 | 2007-11-01 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックスとしてのα−トリフルオロメチルアルコール又はアミン |
US20050230128A1 (en) * | 2004-04-06 | 2005-10-20 | Smith Bret A | Replaceable trench blade |
DE102004055633A1 (de) * | 2004-11-12 | 2006-05-18 | Schering Ag | 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
US7417056B2 (en) * | 2004-11-12 | 2008-08-26 | Schering Ag | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents |
SI2056799T1 (sl) * | 2006-08-31 | 2013-11-29 | Bausch & Lomb Incorporated | Sestavki in postopki za zdravljenje ali preprečevanje glavkoma ali njegovega napredovanja |
ATE506061T1 (de) * | 2006-09-11 | 2011-05-15 | Bausch & Lomb | Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien |
-
2008
- 2008-09-03 US US12/203,158 patent/US20090087443A1/en not_active Abandoned
- 2008-09-08 ES ES08799307T patent/ES2424008T3/es active Active
- 2008-09-08 PL PL08799307T patent/PL2203160T3/pl unknown
- 2008-09-08 CN CN2008801181153A patent/CN101878026B/zh not_active Expired - Fee Related
- 2008-09-08 BR BRPI0817472 patent/BRPI0817472A2/pt not_active IP Right Cessation
- 2008-09-08 JP JP2010527006A patent/JP5249336B2/ja not_active Expired - Fee Related
- 2008-09-08 KR KR1020107006613A patent/KR20100065166A/ko not_active Application Discontinuation
- 2008-09-08 DK DK08799307.7T patent/DK2203160T3/da active
- 2008-09-08 SI SI200831060T patent/SI2203160T1/sl unknown
- 2008-09-08 MX MX2010003198A patent/MX2010003198A/es active IP Right Grant
- 2008-09-08 CA CA2699599A patent/CA2699599C/en not_active Expired - Fee Related
- 2008-09-08 WO PCT/US2008/075579 patent/WO2009042377A1/en active Application Filing
- 2008-09-08 PT PT87993077T patent/PT2203160E/pt unknown
- 2008-09-08 EP EP08799307.7A patent/EP2203160B1/en not_active Not-in-force
- 2008-09-08 AU AU2008305407A patent/AU2008305407B2/en not_active Ceased
- 2008-09-18 TW TW097135854A patent/TWI366462B/zh not_active IP Right Cessation
-
2010
- 2010-12-10 HK HK10111521.3A patent/HK1145014A1/xx not_active IP Right Cessation
-
2013
- 2013-09-02 HR HRP20130817AT patent/HRP20130817T1/hr unknown
- 2013-09-18 CY CY20131100809T patent/CY1114479T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20130817T1 (hr) | 2013-09-30 |
DK2203160T3 (da) | 2013-09-02 |
JP2010540538A (ja) | 2010-12-24 |
MX2010003198A (es) | 2010-04-01 |
CA2699599C (en) | 2012-10-23 |
EP2203160A1 (en) | 2010-07-07 |
WO2009042377A1 (en) | 2009-04-02 |
ES2424008T3 (es) | 2013-09-26 |
CA2699599A1 (en) | 2009-04-02 |
CN101878026A (zh) | 2010-11-03 |
HK1145014A1 (en) | 2011-03-25 |
AU2008305407B2 (en) | 2012-12-20 |
BRPI0817472A2 (pt) | 2015-03-24 |
EP2203160B1 (en) | 2013-07-17 |
PL2203160T3 (pl) | 2013-11-29 |
SI2203160T1 (sl) | 2013-11-29 |
JP5249336B2 (ja) | 2013-07-31 |
PT2203160E (pt) | 2013-10-22 |
CN101878026B (zh) | 2013-11-20 |
AU2008305407A1 (en) | 2009-04-02 |
US20090087443A1 (en) | 2009-04-02 |
TWI366462B (en) | 2012-06-21 |
TW200914014A (en) | 2009-04-01 |
KR20100065166A (ko) | 2010-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114479T1 (el) | Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος | |
TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
MX2009013832A (es) | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. | |
CY1110199T1 (el) | Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων | |
BR0315315A (pt) | Método para tratar, prevenir ou controlar uma sìndrome mielodisplásica, método para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
NO20100041L (no) | Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer | |
PH12021551196A1 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
TW200603787A (en) | Topical preparations containing ambroxol | |
CY1114263T1 (el) | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα | |
CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
AR026916A1 (es) | Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales | |
MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
AR069349A1 (es) | Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular | |
MX2010002781A (es) | Combinacion novedosa de angentes terapeuticos. | |
CO2021006482A2 (es) | Ureas cíclicas | |
MX2010003923A (es) | Formulacion farmaceutica de valsartan. | |
MX2010002584A (es) | Derivados de piperidina como agonistas de receptores muscarinicos. | |
BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
HUP0203844A2 (hu) | Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása | |
CY1109939T1 (el) | Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου |